Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients

Marie-Anne Vandenhende; Suzanne Ingle; Margaret May; Geneviève Chene; Robert Zangerle; Ard Van Sighem; M John Gill; Carolynne Schwarze-Zander; Beatriz Hernandez-Novoa; Niels Obel; Ole Kirk; Sophie Abgrall; Jodie Guest; Hasina Samji; Antonella D'Arminio Monforte; Josep M Llibre; Colette Smith; Matthias Cavassini; Greer A Burkholder; Bryan Shepherd; Heidi M Crane; Jonathan Sterne; Philippe Morlat; Antiretroviral Therapy Cohort Collaboration (ART-CC)

doi:10.1097/QAD.0000000000000544

Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients

Marie-Anne Vandenhende, Suzanne Ingle, Margaret May, Geneviève Chene, Robert Zangerle, Ard Van Sighem, M John Gill, Carolynne Schwarze-Zander, Beatriz Hernandez-Novoa, Niels Obel, Ole Kirk, Sophie Abgrall, Jodie Guest, Hasina Samji, Antonella D'Arminio Monforte, Josep M Llibre, Colette Smith, Matthias Cavassini, Greer A Burkholder, Bryan ShepherdHeidi M Crane, Jonathan Sterne, Philippe Morlat, Antiretroviral Therapy Cohort Collaboration (ART-CC)

Department of Clinical Medicine

50 Citations (Scopus)

Abstract

BACKGROUND: The goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortality by suppressing HIV replication. The prognostic value of persistent low-level viremia (LLV), particularly for clinical outcomes, is unknown.

OBJECTIVE: Assess the association of different levels of LLV with virological failure, AIDS event, and death among HIV-infected patients receiving combination ART.

METHODS: We analyzed data from 18 cohorts in Europe and North America, contributing to the ART Cohort Collaboration. Eligible patients achieved viral load below 50 copies/ml within 3-9 months after ART initiation. LLV50-199 was defined as two consecutive viral loads between 50 and 199 copies/ml and LLV200-499 as two consecutive viral loads between 50 and 499 copies/ml, with at least one between 200 and 499 copies/ml. We used Cox models to estimate the association of LLV with virological failure (two consecutive viral loads at least 500 copies/ml or one viral load at least 500 copies/ml, followed by a modification of ART) and AIDS event/death.

RESULTS: Among 17 902 patients, 624 (3.5%) experienced LLV50-199 and 482 (2.7%) LLV200-499. Median follow-up was 2.3 and 3.1 years for virological and clinical outcomes, respectively. There were 1903 virological failure, 532 AIDS events and 480 deaths. LLV200-499 was strongly associated with virological failure [adjusted hazard ratio (aHR) 3.97, 95% confidence interval (CI) 3.05-5.17]. LLV50-199 was weakly associated with virological failure (aHR 1.38, 95% CI 0.96-2.00). LLV50-199 and LLV200-499 were not associated with AIDS event/death (aHR 1.13, 95% CI 0.81-1.68; and aHR 0.95, 95% CI 0.62-1.48, [corrected] respectively).

CONCLUSION: LLV200-499 was strongly associated with virological failure, but not with AIDS event/death. Our results support the US guidelines, which define virological failure as a confirmed viral load above 200 copies/ml.

Original language	English
Journal	AIDS (London, England)
Volume	29
Issue number	3
Pages (from-to)	373-83
Number of pages	11
ISSN	0269-9370
DOIs	https://doi.org/10.1097/QAD.0000000000000544
Publication status	Published - 28 Jan 2015

Keywords

Adult
Anti-Retroviral Agents
Antiretroviral Therapy, Highly Active
Europe
Female
HIV Infections
HIV-1
Humans
Male
Middle Aged
North America
Prognosis
Survival Analysis
Treatment Outcome
Viral Load
Viremia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/QAD.0000000000000544

Cite this

Vandenhende, M-A., Ingle, S., May, M., Chene, G., Zangerle, R., Van Sighem, A., Gill, M. J., Schwarze-Zander, C., Hernandez-Novoa, B., Obel, N., Kirk, O., Abgrall, S., Guest, J., Samji, H., D'Arminio Monforte, A., Llibre, J. M., Smith, C., Cavassini, M., Burkholder, G. A., ... Antiretroviral Therapy Cohort Collaboration (ART-CC) (2015). Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS (London, England), 29(3), 373-83. https://doi.org/10.1097/QAD.0000000000000544

Vandenhende, M-A, Ingle, S, May, M, Chene, G, Zangerle, R, Van Sighem, A, Gill, MJ, Schwarze-Zander, C, Hernandez-Novoa, B, Obel, N , Kirk, O, Abgrall, S, Guest, J, Samji, H, D'Arminio Monforte, A, Llibre, JM, Smith, C, Cavassini, M, Burkholder, GA, Shepherd, B, Crane, HM, Sterne, J, Morlat, P & Antiretroviral Therapy Cohort Collaboration (ART-CC) 2015, 'Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients', AIDS (London, England), vol. 29, no. 3, pp. 373-83. https://doi.org/10.1097/QAD.0000000000000544

@article{b284b393489d4121907bb01a91ead3a9,

title = "Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients",

abstract = "BACKGROUND: The goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortality by suppressing HIV replication. The prognostic value of persistent low-level viremia (LLV), particularly for clinical outcomes, is unknown.OBJECTIVE: Assess the association of different levels of LLV with virological failure, AIDS event, and death among HIV-infected patients receiving combination ART.METHODS: We analyzed data from 18 cohorts in Europe and North America, contributing to the ART Cohort Collaboration. Eligible patients achieved viral load below 50 copies/ml within 3-9 months after ART initiation. LLV50-199 was defined as two consecutive viral loads between 50 and 199 copies/ml and LLV200-499 as two consecutive viral loads between 50 and 499 copies/ml, with at least one between 200 and 499 copies/ml. We used Cox models to estimate the association of LLV with virological failure (two consecutive viral loads at least 500 copies/ml or one viral load at least 500 copies/ml, followed by a modification of ART) and AIDS event/death.RESULTS: Among 17 902 patients, 624 (3.5%) experienced LLV50-199 and 482 (2.7%) LLV200-499. Median follow-up was 2.3 and 3.1 years for virological and clinical outcomes, respectively. There were 1903 virological failure, 532 AIDS events and 480 deaths. LLV200-499 was strongly associated with virological failure [adjusted hazard ratio (aHR) 3.97, 95% confidence interval (CI) 3.05-5.17]. LLV50-199 was weakly associated with virological failure (aHR 1.38, 95% CI 0.96-2.00). LLV50-199 and LLV200-499 were not associated with AIDS event/death (aHR 1.13, 95% CI 0.81-1.68; and aHR 0.95, 95% CI 0.62-1.48, [corrected] respectively).CONCLUSION: LLV200-499 was strongly associated with virological failure, but not with AIDS event/death. Our results support the US guidelines, which define virological failure as a confirmed viral load above 200 copies/ml.",

keywords = "Adult, Anti-Retroviral Agents, Antiretroviral Therapy, Highly Active, Europe, Female, HIV Infections, HIV-1, Humans, Male, Middle Aged, North America, Prognosis, Survival Analysis, Treatment Outcome, Viral Load, Viremia",

author = "Marie-Anne Vandenhende and Suzanne Ingle and Margaret May and Genevi{\`e}ve Chene and Robert Zangerle and {Van Sighem}, Ard and Gill, {M John} and Carolynne Schwarze-Zander and Beatriz Hernandez-Novoa and Niels Obel and Ole Kirk and Sophie Abgrall and Jodie Guest and Hasina Samji and {D'Arminio Monforte}, Antonella and Llibre, {Josep M} and Colette Smith and Matthias Cavassini and Burkholder, {Greer A} and Bryan Shepherd and Crane, {Heidi M} and Jonathan Sterne and Philippe Morlat and {Antiretroviral Therapy Cohort Collaboration (ART-CC)}",

year = "2015",

month = jan,

day = "28",

doi = "10.1097/QAD.0000000000000544",

language = "English",

volume = "29",

pages = "373--83",

journal = "AIDS, Supplement",

issn = "1350-2840",

publisher = "Lippincott Williams & Wilkins",

number = "3",

}

TY - JOUR

T1 - Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients

AU - Vandenhende, Marie-Anne

AU - Ingle, Suzanne

AU - May, Margaret

AU - Chene, Geneviève

AU - Zangerle, Robert

AU - Van Sighem, Ard

AU - Gill, M John

AU - Schwarze-Zander, Carolynne

AU - Hernandez-Novoa, Beatriz

AU - Obel, Niels

AU - Kirk, Ole

AU - Abgrall, Sophie

AU - Guest, Jodie

AU - Samji, Hasina

AU - D'Arminio Monforte, Antonella

AU - Llibre, Josep M

AU - Smith, Colette

AU - Cavassini, Matthias

AU - Burkholder, Greer A

AU - Shepherd, Bryan

AU - Crane, Heidi M

AU - Sterne, Jonathan

AU - Morlat, Philippe

AU - Antiretroviral Therapy Cohort Collaboration (ART-CC)

PY - 2015/1/28

Y1 - 2015/1/28

N2 - BACKGROUND: The goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortality by suppressing HIV replication. The prognostic value of persistent low-level viremia (LLV), particularly for clinical outcomes, is unknown.OBJECTIVE: Assess the association of different levels of LLV with virological failure, AIDS event, and death among HIV-infected patients receiving combination ART.METHODS: We analyzed data from 18 cohorts in Europe and North America, contributing to the ART Cohort Collaboration. Eligible patients achieved viral load below 50 copies/ml within 3-9 months after ART initiation. LLV50-199 was defined as two consecutive viral loads between 50 and 199 copies/ml and LLV200-499 as two consecutive viral loads between 50 and 499 copies/ml, with at least one between 200 and 499 copies/ml. We used Cox models to estimate the association of LLV with virological failure (two consecutive viral loads at least 500 copies/ml or one viral load at least 500 copies/ml, followed by a modification of ART) and AIDS event/death.RESULTS: Among 17 902 patients, 624 (3.5%) experienced LLV50-199 and 482 (2.7%) LLV200-499. Median follow-up was 2.3 and 3.1 years for virological and clinical outcomes, respectively. There were 1903 virological failure, 532 AIDS events and 480 deaths. LLV200-499 was strongly associated with virological failure [adjusted hazard ratio (aHR) 3.97, 95% confidence interval (CI) 3.05-5.17]. LLV50-199 was weakly associated with virological failure (aHR 1.38, 95% CI 0.96-2.00). LLV50-199 and LLV200-499 were not associated with AIDS event/death (aHR 1.13, 95% CI 0.81-1.68; and aHR 0.95, 95% CI 0.62-1.48, [corrected] respectively).CONCLUSION: LLV200-499 was strongly associated with virological failure, but not with AIDS event/death. Our results support the US guidelines, which define virological failure as a confirmed viral load above 200 copies/ml.

AB - BACKGROUND: The goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortality by suppressing HIV replication. The prognostic value of persistent low-level viremia (LLV), particularly for clinical outcomes, is unknown.OBJECTIVE: Assess the association of different levels of LLV with virological failure, AIDS event, and death among HIV-infected patients receiving combination ART.METHODS: We analyzed data from 18 cohorts in Europe and North America, contributing to the ART Cohort Collaboration. Eligible patients achieved viral load below 50 copies/ml within 3-9 months after ART initiation. LLV50-199 was defined as two consecutive viral loads between 50 and 199 copies/ml and LLV200-499 as two consecutive viral loads between 50 and 499 copies/ml, with at least one between 200 and 499 copies/ml. We used Cox models to estimate the association of LLV with virological failure (two consecutive viral loads at least 500 copies/ml or one viral load at least 500 copies/ml, followed by a modification of ART) and AIDS event/death.RESULTS: Among 17 902 patients, 624 (3.5%) experienced LLV50-199 and 482 (2.7%) LLV200-499. Median follow-up was 2.3 and 3.1 years for virological and clinical outcomes, respectively. There were 1903 virological failure, 532 AIDS events and 480 deaths. LLV200-499 was strongly associated with virological failure [adjusted hazard ratio (aHR) 3.97, 95% confidence interval (CI) 3.05-5.17]. LLV50-199 was weakly associated with virological failure (aHR 1.38, 95% CI 0.96-2.00). LLV50-199 and LLV200-499 were not associated with AIDS event/death (aHR 1.13, 95% CI 0.81-1.68; and aHR 0.95, 95% CI 0.62-1.48, [corrected] respectively).CONCLUSION: LLV200-499 was strongly associated with virological failure, but not with AIDS event/death. Our results support the US guidelines, which define virological failure as a confirmed viral load above 200 copies/ml.

KW - Adult

KW - Anti-Retroviral Agents

KW - Antiretroviral Therapy, Highly Active

KW - Europe

KW - Female

KW - HIV Infections

KW - HIV-1

KW - Humans

KW - Male

KW - Middle Aged

KW - North America

KW - Prognosis

KW - Survival Analysis

KW - Treatment Outcome

KW - Viral Load

KW - Viremia

U2 - 10.1097/QAD.0000000000000544

DO - 10.1097/QAD.0000000000000544

M3 - Journal article

C2 - 25686685

SN - 1350-2840

VL - 29

SP - 373

EP - 383

JO - AIDS, Supplement

JF - AIDS, Supplement

IS - 3

ER -

Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this